Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: A retrospective analysis of a double-blind trial and an open-label extension

Drug Safety

Volumn 31, Issue 1, 2008, Pages 79-94

  Oertel, Wolfgang ^a   Poewe, Werner ^b   Wolters, Erik ^c   De Deyn, Peter Paul ^d   Emre, Murat ^e   Kirsch, Courtney ^f   Hsu, Chuanchieh ^f   Tekin, Sibel ^f   Lane, Roger ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e ISTANBUL UNIVERSITY   (Turkey)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cholinergic receptor agonists, therapeutic use; Dementia, management; Parkinson's disease; Rivastigmine, adverse reactions; Rivastigmine, therapeutic use

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE;

AGED; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; POST HOC ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 37549040877     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831010-00007     Document Type: Article

References (43)

1. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998; 339: 1044-53
2. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413-21
3. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction diseases with Lewy bodies. Neurology 2000; 54: 407-11
4. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-8
5. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-6
6. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease. Curr Med Res Opin 2002; 18: 258-64
7. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-95
8. Fogelson N, Kogan E, Korczyn AD, et al. Effects of rivastigmine on the quantitative EEG in demented parkinsonian patients. Acta Neurol Scand 2003; 107: 252-5
9. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson's disease. Expert Opin Pharmacother 2003; 4: 1747-61
10. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007; 74: 1235-46
11. Millan MJ, DiCara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007; 100: 1047-61
12. Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60: 337-41
13. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540-3
14. Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002; 23: 245-54
15. Glowinski J. Recent finding on dopaminergic transmission in the basal ganglia. Adv Neurol 1990; 53: 67-73
16. Liang YQ, Tang XC. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 2006; 27: 1127-36
17. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for the dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 29-38
18. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006; 21: 456-61
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
20. Fahn S, Elton RL and Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information, 1987: 153-64
21. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S33-9
22. Brønnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia associated with PD. J Neurol Neurosurg Psychiatry 2006; 77: 1136-42
23. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-907
24. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-5
25. Alves G, Wentzel-Larsen T, Aarsland D, et al. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005; 65: 1436-41
26. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962; 87: 802-7
27. Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967; 17: 124-36
28. Touchon J, Bergman H, Bullock R, et al. Response to rivastigmine or donepezil in patients with Alzheimer's disease and symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006; 22: 49-59
29. Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neuro Scand 2003; 108: 367-73
30. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized double-blind, placebo controlled international study. Lancet 2000; 356: 2031-6
31. Gurevich TY, Shabtai H, Korczyn AD, et al. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Mov Disord 2006; 21: 1663-6
32. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-8
33. Bullock R, Lane R. Executive dyscontrol of dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4: 277-93
34. Dubois B, Tolosa E, Kulisevsky J, et al. Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia [poster presentation]. 8th International Conference on Alzheimer's and Parkinson's Diseases; 2007 Mar 14-18; Salzburg
35. Richards M, Stern Y, Marder K, et al. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal elderly individuals. Ann Neurol 1993; 33: 267-74
36. Wilson RS, Schneider JA, Bienias JL, et al. Parkinsonian like signs and risk of incident Alzheimer disease in older persons. Arch Neurol 2003; 60: 539-44
37. Wilson RS, Bennett DA, Gilley DW, et al. Progression of parkinsonian signs in Alzheimer's disease. Neurology 2000; 54: 1284-9
38. Fleischman DA, Wilson RS, Bienias JL, et al. Parkinsonian signs and cognitive function in old age. J Int Neuropsychol Soc 2005; 11: 591-7
39. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21: 1123-30
40. Deuschl G, Raethjen J, Baron R, et al. The pathophysiology of parkinsonian tremor: a review. J Neurol 2000; 247 Suppl. 5: V33-48
41. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-12
42. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomized, double-blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-9
43. Lahti AC, Holcomb HH, Weiler MA, et al. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry 2003; 53: 601-8